With Avastin Approval For Breast Cancer, Will More Patients Hit Price Cap?
• By Brian Marson
FDA approval of Genentech's Avastin for first-line treatment of metastatic breast cancer may trigger the first significant trial of the biotech's Avastin patient assistance program, which caps annual drug expenditures at $55,000 for approved indications but has not seen much utilization by colorectal or non-small cell lung cancer patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights